EPISODE
01:39:20 Noor Siddiqui, founder and CEO of Orchid, a reproductive technology company, discusses how Orchid's whole-genome embryo screening empowers prospective parents to assess and mitigate genetic risks before pregnancy, aiming to shift reproductive healthcare from reactive to proactive. She highlights that traditional IVF provides limited information, whereas Orchid's platform sequences over 99% of an embryo's genome, offering insights into more than 1,200 conditions, including heart defects, pediatric cancers, and neurodevelopmental disorders. Siddiqui emphasizes that this technology enables parents to make informed decisions, potentially reducing the incidence of genetic diseases and associated suffering.